SAN DIEGO – ResMed Inc. results for quarter ended June 30, 2023 indicated that revenue increased by 23% to $1.1 billion; up 23% on a constant currency basis.
“ResMed’s fourth quarter and full-year 2023 results reflect strong double-digit growth as we continue to produce and deliver cloud-connected flow generator device volume to meet the ongoing strong global demand from patients, accompanied by high growth of our market-leading patient interface and software solutions,” said Mick Farrell, chairman and CEO of ResMed via press release. “The combined global supply of our cloud-connected platforms, AirSense10 and AirSense11, have enabled us to support customer demand for CPAP and APAP devices across the global market.
“The strong growth of our mask and patient interfaces business was supported by new patient setups as well as ongoing resupply activity as we focus on increasing therapy adherence to improve patient outcomes and quality-of-life,” Farrell continued. “Our residential medicine software-as-a-service business continues to achieve high-single-digit growth organically expanding to solid double-digit growth including the contribution from MEDIFOX DAN. As we turn to fiscal year 2024, our focus remains on delivering world-leading therapy and digital health solutions so that even more people are able to sleep better, breathe better, and live higher-quality lives outside the hospital, preferably in their own home.”